Skip to content
Evigrade
ModerateVitamin K antagonist anticoagulants×Amphenicol antibiotic for systemic use

Updated · Methodology

Mechanism

Acenocoumarol is a coumarin derivative and vitamin K antagonist: it reduces the activation of the vitamin K-dependent clotting factors II, VII, IX and X. Its effect is measured by the prothrombin time and the international normalised ratio (INR) (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish acenocoumarol SmPCs list chloramphenicol among antibiotics that can potentiate acenocoumarol but do not describe a mechanism for it. The originator acenocoumarol SmPC lists general mechanisms of coumarin interactions: impaired absorption, inhibition or induction of liver enzymes, mainly CYP2C9, and reduced availability of vitamin K (acenocoumarol SmPCs, AEMPS). The chloramphenicol documents say nothing about anticoagulants. In Spain, chloramphenicol is available only as eye ointments and as skin ointments with hydrocortisone. Among interactions, the US label for intravenous chloramphenicol names only drugs that may cause bone marrow depression (chloramphenicol SmPCs, AEMPS; chloramphenicol prescribing information, US Food and Drug Administration, FDA). Infection and inflammation can reduce the protein binding of acenocoumarol, so strict medical supervision is needed during such periods (acenocoumarol SmPC, AEMPS).

Symptoms

The main risk is bleeding, because chloramphenicol can potentiate acenocoumarol. Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an international normalised ratio (INR) above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol summaries of product characteristics, SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal, uterine, nose and gum bleeding, vomiting blood and bleeding into joints (AEMPS). Chloramphenicol itself can cause serious, sometimes fatal, blood dyscrasias such as aplastic anaemia, thrombocytopenia and granulocytopenia (chloramphenicol prescribing information, US Food and Drug Administration, FDA). After topical use such reactions are rare, but bone marrow aplasia has also occurred after the eye ointment (chloramphenicol eye ointment SmPC, AEMPS).

Management

The combination is not contraindicated but needs frequent coagulation monitoring. The acenocoumarol summaries of product characteristics (SmPCs) ask for close and frequent coagulation checks, for example twice a week. This applies both when chloramphenicol is added and when it is stopped (acenocoumarol SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). The acenocoumarol SmPCs do not specify the chloramphenicol formulation (AEMPS). The Spanish chloramphenicol ointment SmPCs say nothing about anticoagulants (AEMPS). According to the eye ointment SmPC, chloramphenicol applied to the eye can be absorbed into the aqueous humour and reach the systemic circulation. Specific data on systemic absorption are lacking. According to the SmPC of the skin ointment with hydrocortisone, absorption of a very small amount through damaged skin cannot be excluded (chloramphenicol SmPCs, AEMPS). During intravenous chloramphenicol treatment, do baseline blood tests and repeat them about every two days. Stop chloramphenicol if reticulocytopenia, leukopenia, thrombocytopenia, anaemia or other blood changes attributable to it appear (chloramphenicol prescribing information, US Food and Drug Administration, FDA). Acenocoumarol is contraindicated in thrombocytopenia with a platelet count below 50 × 10⁹/L (acenocoumarol SmPC, AEMPS). Adjust the acenocoumarol dose by the prothrombin time and the international normalised ratio (INR). A dose change does not show in the prothrombin time for at least 36 hours. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Acenocoumarol